Published in J Transl Med on June 13, 2013
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res (2015) 0.93
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology (2015) 0.91
From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 0.90
Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies. Front Immunol (2014) 0.88
IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget (2015) 0.84
Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. Oncoimmunology (2014) 0.83
B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. Int J Clin Exp Pathol (2015) 0.81
Anti-α-enolase is a prognostic marker in postoperative lung cancer patients. Oncotarget (2015) 0.81
The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration. Br J Cancer (2014) 0.81
The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumour Biol (2016) 0.77
Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro. J Transl Med (2016) 0.77
Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. Oncoimmunology (2015) 0.77
The expression of Duffy antigen receptor for chemokines by epithelial ovarian cancer decreases growth potential. Oncol Lett (2017) 0.76
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer. Oncoimmunology (2016) 0.75
CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget (2017) 0.75
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. J Gynecol Oncol (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 4.69
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 3.84
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med (2001) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood (2005) 3.26
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 2.85
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol (2005) 2.48
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer (2010) 2.43
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 2.42
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol (2006) 2.05
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (2005) 2.01
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 2.00
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 1.98
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol (2009) 1.98
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res (2005) 1.82
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol (2002) 1.82
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 1.72
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 1.68
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol (2007) 1.68
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 1.68
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol (2006) 1.55
Tumour macrophages as potential targets of bisphosphonates. J Transl Med (2011) 1.53
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev (2007) 1.50
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood (2012) 1.46
Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun (1997) 1.44
The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev (2008) 1.43
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer (2010) 1.43
The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood (2006) 1.41
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol (2004) 1.31
Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol (2006) 1.31
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
Conservation of Arabidopsis flowering genes in model legumes. Plant Physiol (2005) 1.98
The branching gene RAMOSUS1 mediates interactions among two novel signals and auxin in pea. Plant Cell (2005) 1.85
Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol (2009) 1.77
Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol (2009) 1.48
Towards a unified genetic map for diploid roses. Theor Appl Genet (2010) 1.42
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol (2014) 1.41
The TFL1 homologue KSN is a regulator of continuous flowering in rose and strawberry. Plant J (2011) 1.37
FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div (2007) 1.13
CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res (2013) 1.07
DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells. Eur J Immunol (2009) 1.03
The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest (2002) 1.02
Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther (2011) 1.00
Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother (2007) 1.00
Intra-operative touch preparation cytology following lumpectomy for breast cancer: a series of 400 procedures. Breast (2009) 0.99
Transcriptome database resource and gene expression atlas for the rose. BMC Genomics (2012) 0.97
Phenotypic variability of a 4q34-->qter inherited deletion: MRKH syndrome in the daughter, cardiac defect and Fallopian tube cancer in the mother. Eur J Med Genet (2006) 0.96
A survey of flowering genes reveals the role of gibberellins in floral control in rose. Theor Appl Genet (2009) 0.96
Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol (2008) 0.95
MLL-SEPT5 fusion transcript in infant acute myeloid leukemia with t(11;22)(q23;q11). Leuk Lymphoma (2013) 0.94
The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism. Haematologica (2005) 0.92
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro Oncol (2012) 0.91
Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res (2005) 0.89
The cryptochrome gene family in pea includes two differentially expressed CRY2 genes. Plant Mol Biol (2005) 0.89
Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases. Anticancer Res (2008) 0.88
Impacts of light and temperature on shoot branching gradient and expression of strigolactone synthesis and signalling genes in rose. Plant Cell Environ (2013) 0.87
Photocontrol of bud burst involves gibberellin biosynthesis in Rosa sp. J Plant Physiol (2012) 0.87
Genomic approach to study floral development genes in Rosa sp. PLoS One (2011) 0.87
Histologic prognostic factors associated with chromosomal imbalances in a contemporary series of 89 clear cell renal cell carcinomas. Hum Pathol (2013) 0.86
5q12.1 deletion: delineation of a phenotype including mental retardation and ocular defects. Am J Med Genet A (2011) 0.86
Pure flat epithelial atypia (DIN 1a) on core needle biopsy: study of 60 biopsies with follow-up surgical excision. Breast Cancer Res Treat (2010) 0.85
Comparison of the immunomodulatory effects of L. donovani and L. major excreted-secreted antigens, particulate and soluble extracts and viable parasites on human dendritic cells. Vaccine (2008) 0.84
Quantitative trait loci for flowering time and inflorescence architecture in rose. Theor Appl Genet (2010) 0.83
RoKSN, a floral repressor, forms protein complexes with RoFD and RoFT to regulate vegetative and reproductive development in rose. New Phytol (2013) 0.83
Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas. Am J Surg Pathol (2004) 0.82
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. J Immunother (2010) 0.82
All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. Nephrol Dial Transplant (2013) 0.82
Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow-up surgical excision. Breast (2007) 0.81
Daily regulation of serum and urinary hepcidin is not influenced by submaximal cycling exercise in humans with normal iron metabolism. Eur J Appl Physiol (2009) 0.81
[Medical treatment of a voluminous tumor of the mesenteric root]. Gastroenterol Clin Biol (2003) 0.81
Occurrence of endometrial cancer six years after treatment with thermal balloon ablation (Thermachoice): first case report. Eur J Obstet Gynecol Reprod Biol (2010) 0.79
Gibberellins regulate the transcription of the continuous flowering regulator, RoKSN, a rose TFL1 homologue. J Exp Bot (2012) 0.79
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy. Int J Cancer (2011) 0.79
CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells. J Immunol (2013) 0.78
Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. Int J Gynecol Cancer (2014) 0.78
Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge. Cancer Chemother Pharmacol (2009) 0.78
Immunostimulatory properties of dendritic cells after Leishmania donovani infection using an in vitro model of liver microenvironment. PLoS Negl Trop Dis (2010) 0.78
[Angiotensin-2 type 1 receptors (AT1R) and cancers]. Nephrol Ther (2013) 0.78
Common chromosomal abnormalities in mycosis fungoides transformation. Genes Chromosomes Cancer (2007) 0.77
Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma. Eur J Med Genet (2013) 0.77
[Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes]. Med Sci (Paris) (2010) 0.75
Radioisotopic location of the sentinel node in vaginal mucous melanoma before laparoscopic sampling. Surg Laparosc Endosc Percutan Tech (2008) 0.75
A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients. PLoS One (2013) 0.75
Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5. J Gene Med (2008) 0.75
Intraoperative touch imprint cytology of axillary sentinel nodes for breast cancer: a series of 355 procedures. Breast (2010) 0.75
Patient age and positive margins are predictive factors of residual tumor on mastectomy specimen after conservative treatment for breast cancer. Breast (2009) 0.75
Factors Associated with Fecal Incontinence in Women of Childbearing Age with Crohn's Disease. Inflamm Bowel Dis (2017) 0.75
A multi-modal assessment of a multi-visceral affect of a Wegener granulomatosis. Eur Heart J (2009) 0.75
Isolated skin recurrence following salvage mastectomy for intramammary recurrence (after initial breast conservation therapy): is it a fatal event? Breast (2011) 0.75
Terminal 6.9 Mb deletion of chromosome 15q, associated with a structurally abnormal X chromosome in a patient with congenital diaphragmatic hernia and heart defect. Eur J Med Genet (2010) 0.75
Involvement of ITIH5, a candidate gene for congenital uterovaginal aplasia (Mayer-Rokitansky-Küster-Hauser syndrome), in female genital tract development. Gene Expr (2012) 0.75
Which Donor for Uterus Transplants: Brain-Dead Donor or Living Donor? A Systematic Review. Transplantation (2017) 0.75
The Accuracy of Large Loop Excision of the Transformation Zone Specimen Dimensions in Determining Volume: A Multicentric Prospective Observational Study. J Low Genit Tract Dis (2016) 0.75
[Composite lymphoma: association of a follicular lymphoma and a chronic lymphocytic leukemia]. Ann Pathol (2008) 0.75